Competitive Strategies in an Era of Consolidation & Disruptive Technologies
|出版日||ページ情報||英文 100 Pages
|統合&ディスラプティブ技術の時代における競合戦略 Competitive Strategies in an Era of Consolidation & Disruptive Technologies|
|出版日: 2014年08月14日||ページ情報: 英文 100 Pages||
BioInformatics LLC, the leading research and advisory firm serving the life science tools market, will conduct an unprecedented analysis of competitive strategies in an era of flat growth, Thermo Fisher Scientific's acquisition of Life Technologies, other mergers, and disruptive technologies. This prospectus highlights the objectives and methodology of the research effort and the analysis and actionable strategies that will be delivered in the final report.
The life science tools market has been in a near constant state of flux over the past five years as established companies have merged or been acquired, new companies are founded, and emerging technologies (such as next generation sequencing) disrupt long established markets and create new opportunities. All of this change is layered over constrained research funding in the United States and Europe and increased levels of life science spending and investment in Asia.
This market turbulence came to a head when in April 2013 Thermo Fisher Scientific (TMO) announced that it planned to acquire Life Technologies (LIFE) in a $13.6 billion transaction. On February 3, 2014, the deal closed and a $17 billion company focused on the life sciences emerged. Completion of the transaction followed the receipt of all the required regulatory approvals and included the sale of the cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for $1.07 billion. This constant state of disruption can be confusing for customers, challenging for the merging companies, and (if played appropriately) moments of opportunity for competitors.
Life science tools companies have had a year to determine how to compete in this new market that is dominated by one very large competitor with enhanced scale, impressive channel access, and the breadth and depth of capabilities to meet customer needs in research, specialty diagnostics and applied markets. Mergers are one way for companies to respond to external market conditions that reward scale, size and cost-effectiveness. The prevailing question that this report seeks to answer is: How should life science tools companies compete in this new market environment?
In light of these questions, which business strategies might be implemented?
The purpose of this study is to take the pulse of the life science ecosystem to discern the effects of recent mergers, overall low growth, and disruptive technologies on suppliers and customers.
Mega-mergers tend to weed out marginal competitors and create opportunities for those astute enough to know what is happening around them. Multi-sponsor market research enables companies to quickly gain competitive advantage through insights that support strategic decisionmaking - at a fraction of the cost of a custom research project. Multi-sponsor research is the concept of sharing the costs and the results with a select group of market participants at a significant discount months before the results are released for general sale.
BioInformatics LLC has a multidisciplinary team of scientists, industry veterans and market research experts who will begin work upon receipt of your Sponsorship Agreement.
BioInformatics LLC has unmatched expertise in the life science market and has delivered market studies to more than 500 unique firms.
BioInformatics LLC multi-sponsor research projects are unbiased and provide a fresh perspective on your strategies.
There is no need for pre-publication sponsors to disrupt their routine activities. BioInformatics LLC will perform all aspects of the research and deliver the final report within the required timeframe.
To commission a private study of similar scale and scope would cost approximately $80,000 to $100,000 USD.